United Therapeutics Reports Record Q3 2026 Revenue Driven by Tyvaso Growth
United Therapeutics (UTHR) reported record total revenue of $833 million for the third quarter of 2026. A significant driver of this performance was the Tyvaso product line, which generated record revenues of $504 million, reflecting strong sequential growth and robust underlying market demand. Looking toward future expansion, the company announced plans to submit a New Drug Application (NDA) for its soft mist inhaler in 2027. Management identified approximately 1 million potential patients across key U.S. expansion markets, signaling long-term growth prospects through new delivery technologies.
Tickers: $UTHR
Topics: earnings financial performance revenue